0001493152-24-006338.txt : 20240214 0001493152-24-006338.hdr.sgml : 20240214 20240214083440 ACCESSION NUMBER: 0001493152-24-006338 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240214 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VBI Vaccines Inc/BC CENTRAL INDEX KEY: 0000764195 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37769 FILM NUMBER: 24632601 BUSINESS ADDRESS: STREET 1: 160 SECOND STREET STREET 2: CAMBRIDGE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-830-3031 MAIL ADDRESS: STREET 1: 160 SECOND STREET STREET 2: CAMBRIDGE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: SciVac Therapeutics Inc. DATE OF NAME CHANGE: 20150717 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD. DATE OF NAME CHANGE: 20100910 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD DATE OF NAME CHANGE: 19850305 8-K 1 form8-k.htm
false VBI Vaccines Inc/BC 0000764195 0000764195 2024-02-14 2024-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 14, 2024

 

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   001-37769   N/A
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

160 Second Street, Floor 3

Cambridge, Massachusetts

   02142
(Address of principal executive offices)   (Zip Code)

 

(617) 830-3031

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Shares, no par value per share   VBIV   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On February 13, 2024, VBI Vaccines Inc. (the “Company”) entered into (i) an amendment to the Company’s loan agreement with K2 HealthVentures LLC (“K2HV”), (ii) a Purchase Agreement (“Brii Purchase Agreement”) among the Company, Variation Biotechnologies Inc., a Canadian federal corporation (“VBI Cda”) and Brii Biosciences Limited, an exempted company organized under the laws of the Cayman Islands (“Brii Bio”), (iii) a Purchase Agreement (“Rehovot Purchase Agreement”) among the Company, SciVac Ltd., an Israeli company (“SciVac”), Brii Biosciences, Inc., a Delaware corporation (“Brii Subsidiary”) and a wholly-owned subsidiary of Brii Bio to be formed in Israel and joined as a party to the Rehovot Purchase Agreement and (iv) a side letter (“Side Letter”) with Brii Bio.

 

Amendment to Loan Agreement

 

As previously disclosed, the Company and its subsidiary VBI Cda, as borrowers, entered into a Loan and Guaranty Agreement dated as of May 22, 2020, as amended by the first amendment, dated as of May 17, 2021, that second amendment, dated as of September 14, 2022, and that third amendment, dated as of July 5, 2023, and as such agreement may be amended from time to time in the future (collectively, the “Loan Agreement”) with K2HV and any other lenders party thereto from time to time (collectively, the “Loan Parties”) with the obligations under the Loan Agreement secured on a senior basis by a lien on substantially all of the assets of the Company and its subsidiaries.

 

On February 13, 2024, the Loan Parties entered into an amendment (the “Fourth Amendment”) to the Loan Agreement pursuant to which the parties have agreed to, among other things, (i) remove a financial covenant requiring the Company to maintain minimum net revenue of 75% of projections, (ii) the forbearance by K2HV and the other lenders party thereto, prior to the earlier of (A) December 31, 2024, (B) the date the Side Letter ceases to be in full force and effect prior to the completion of the Essential Activities (as defined below) and (C) the date the Essential Activities are complete (the “Forbearance Expiration Date”) from exercising their remedies with respect to the occurrence of Events of Default subject to certain exceptions, and (iii) following the Forbearance Expiration Date, add a financial covenant requiring the Company to maintain a minimum cash amount equal to its obligations under the Loan Agreement at all times.

 

The entry into the Brii Purchase Agreement, the Side Letter, and the Rehovot Purchase Agreement set forth in this this Current Report on Form 8-K (the “Report”) are conditions to the effectiveness of the Fourth Amendment.

 

Brii Purchase Agreement

 

On February 13, 2024, the Company and VBI Cda entered into the Brii Purchase Agreement with Brii Bio, pursuant to which, the Company and VBI Cda will sell, transfer, convey and assign to Brii Bio, substantially all of the intellectual property related to VBI-2601 owned by the Company and VBI Cda, for a secured promissory note in the principal amount up to $10,000,000 (the “Note”) to be issued by Brii Bio, which is then required to be assigned to K2HV pursuant to the terms of the Fourth Amendment, in exchange for a reduction in the Company’s obligations under the Loan Agreement equal to the initial principal amount of the Note. The initial principal amount of the Note will be $2,500,000, which shall be increased by an aggregate amount equal to $7,500,000 upon the Company obtaining applicable consents under the License Agreement, dated as of September 1, 2021, by and among Ferring International Center S.A., SciVac, and the Company. In the event of certain breaches by VBI of the Brii Purchase Agreement and any such breach is not cured with 30 days, the aggregate principal amount of the Note shall be reduced by an aggregate amount equal to $2,500,000.

 

 
 

 

In addition to the foregoing, the Purchase Agreement contains certain amendments to the Company’s previously announced collaboration agreements with Brii Bio, which are further described below.

 

Amendments to Collaboration and License Agreement

 

As previously disclosed on July 5, 2023, the Company and Brii Bio entered into a Collaboration and License Agreement (the “Collaboration Agreement”), pursuant to which, among other things, subject to the terms and conditions set forth in the Collaboration Agreement, the Company and Brii Bio agreed to collaborate on the further development of PreHevbri (“Licensed Product”), a three antigen vaccine for use in the field of the prevention of Hepatitis B in the licensed territory, which consists of the Asia Pacific region other than Japan.

 

Pursuant to the Brii Purchase Agreement, on February 13, 2024, the Company and Brii Bio agreed to amend the Collaboration Agreement to, among other things, subject to the terms and conditions set forth in the Collaboration Agreement, (i) amend the terms of the royalty bearing license granted by the Company to Brii Bio for the global development activities of the Licensed Product to be “perpetual and irrevocable”, (ii) omit the requirement for Brii Bio to obtain marketing approval for the Licensed Product in certain territories and (iii) omit the requirement for Brii Bio to make royalty and milestone payments to the Company.

 

Amendments to the Amended & Restated Collaboration and License Agreement

 

As previously disclosed, on December 4, 2018, the Company and Brii Bio entered into a Collaboration and License Agreement (the “Original Collaboration Agreement”), pursuant to which the Company and Brii Bio agreed to collaborate on the development of a Hepatitis B recombinant protein-based immunotherapeutic in the licensed territory, which consists of China, Hong Kong, Taiwan, and Macau (collectively, the “VBI-2601 Licensed Territory”).

 

Further, as previously disclosed, on July 5, 2023, the Company and Brii Bio agreed to amend and restate the Original Collaboration Agreement (the “A&R Collaboration Agreement”), to, among other things, subject to the terms and conditions set forth in the A&R Collaboration Agreement, expand the VBI-2601 Licensed Territory to the entire world for Brii Bio’s exclusive rights and licenses to make, have made, use, sell, offer for sale, and import VBI-2601.

 

Pursuant to the Brii Purchase Agreement, on February 13, 2024, the Company and Brii Bio agreed to amend the A&R Collaboration Agreement to, among other things, subject to the terms and conditions set forth in the A&R Collaboration Agreement, (i) amend the terms the royalty bearing license granted by the Company to Brii Bio for research studies and development of VBI-2601 to be “perpetual and irrevocable”, (ii) omit the requirement for Brii Bio to obtain marketing approval and commercialize VBI-2601 in the United States and China, (iii) revise the indemnity requirements such that Brii Bio indemnifies the Company with respect to certain transferred intellectual property after the effective date of the Brii Purchase Agreement and the Company indemnifies Brii Bio prior to such date,(iv) omit the requirement for Brii Bio to make royalty and milestone payments to the Company and (v) omit certain rights of the Company to terminate the A&R Collaboration Agreement and certain other effects of termination of the A&R Collaboration Agreement.

 

 
 

 

Side Letter

 

On February 13, 2024, the Company and Brii Bio entered into the Side Letter setting forth certain essential and additional priority activities to transfer manufacturing responsibility for clinical supply and commercial supply of VBI-2601 and PreHevbri for the Brii Territories set forth in the Side Letter (the “Essential Activities”) the Company is required to complete as a condition to the entry into the License Agreement and consummation of the transactions pursuant to the Rehovot Purchase Agreement. The principal amount of the Note shall increase up to $18,000,000 upon completion of the Essential Activities and the Company’s obligations under the Loan Agreement shall be reduced by a corresponding amount.

 

License Agreement

 

Upon completion of the Essential Activities, VBI Cda and Brii Brio will enter into a license agreement (the “License Agreement”) pursuant to which VBI Cda will grant Brii Bio a perpetual, royalty-free, milestone-free, sublicensable, fully-paid, and exclusive license to the GBM Program (VBI-1901) for development and commercialization in the Asia-Pacific (APAC) region (excluding Japan), for a secured promissory note in the principal amount of $5,000,000 to be issued by Brii Bio, which is then required to be assigned to K2HV pursuant to the terms of the Fourth Amendment, in exchange for a reduction in the Company’s obligations under the Loan Agreement equal to the initial principal amount of such note.

 

The entry by VBI Cda and Brii Brio into the License Agreement is subject to the Company completing the Essential Activities.

 

Rehovot Purchase Agreement

 

On February 13, 2024, the Company and SciVac (the “Seller”) entered into the Rehovot Purchase Agreement with a wholly-owned subsidiary of Brii Bio to be formed in Israel prior to the closing and joined as a party to the agreement prior to the closing as the purchaser (the “Purchaser”) and Brii Subsidiary, pursuant to which, upon closing of the transactions contemplated by the Rehovot Purchase Agreement, the Seller will sell to the Purchaser certain assets including Seller and its affiliates’ interest and rights in and to certain assets and leases with respect to a vaccine manufacturing facility in Israel, for an aggregate purchase price of $10,000,000, which is then required to be paid to K2HV pursuant to the terms of the Fourth Amendment.

 

The Rehovot Purchase Agreement contains representations and warranties of the Seller and Purchaser that are typical for transactions of this type. The Rehovot Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type.

 

The closing of the transactions pursuant to the Rehovot Purchase Agreement are subject to closing conditions that are typical for transactions of this type, including the Company completing the Essential Activities and closing will not occur prior to June 30, 2024.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference in this Item 2.03.

 

Item 3.03 Material Modification to Rights of Security Holders.

 

The information required by this Item 3.03 is contained in Item 1.01 and is incorporated by reference herein.

 

Item 8.01 Other Events.

 

On February 14, 2024, the Company issued a press release announcing its entry into the Brii Purchase Agreement, amendment to the Collaboration Agreements, amendment to A&R Collaboration Agreement, Rehovot Purchase Agreement and the Fourth Amendment. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated February 14, 2024 (furnished pursuant to Item 8.01)
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VBI Vaccines Inc.
     
Date: February 14, 2024 By: /s/ Jeffrey R. Baxter
    Jeffrey R. Baxter
    President and Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

 

●VBI to receive up to $33 million in consideration, subject to achievement of certain activities, for:

 

◌VBI’s manufacturing capabilities and certain related assets at Rehovot manufacturing facility
◌Intellectual property for VBI-2601, VBI’s hepatitis B immunotherapeutic candidate
◌Exclusive Asia Pacific (APAC), excluding Japan, license for development and commercialization of VBI-1901, VBI’s glioblastoma immunotherapeutic candidate

 

●Following completion of the full transaction, VBI expects its total debt principal under its current facility with K2 HealthVentures to be significantly reduced to $17 million

 

CAMBRIDGE, Mass. (February 14, 2024) – VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced agreements whereby Brii Biosciences (“Brii Bio”), subject to certain activities, is expected to: (i) acquire the intellectual property for VBI-2601, VBI’s HBV immunotherapeutic development program, and eliminate payment obligations from the July 2023 agreements between VBI and Brii Bio, (ii) acquire manufacturing capabilities and certain related assets at VBI’s Rehovot, Israel manufacturing facility, and (iii) enter into an exclusive license to develop and commercialize VBI-1901, VBI’s glioblastoma (GBM) immunotherapeutic candidate, in the Asia Pacific region (APAC), excluding Japan. Additionally, subject to certain approvals, VBI and Brii Bio will work together to transfer the manufacturing technologies of VBI-2601 to a site designated by Brii Bio. VBI received $2.5 million of consideration upon signing of definitive documents and is expected to receive up to an additional $30.5 million of consideration, subject to achievement of certain activities, with a target completion date of June 30, 2024.

 

Jeff Baxter, President and CEO of VBI, stated: “We believe that this transaction improves the financial stability of VBI and balances the potential value creation within our development and commercial portfolio with a streamlined and focused resource deployment. Upon successful completion of all transactions, we anticipate that we will have reduced the long-term burn of the company, and reduced our debt overhang by about 70%. We remain steadfast in our belief that our pipeline can have a meaningful impact on patients, providers, and public health, and we believe this deal better positions us to deliver on this mission.”

 

The proceeds from these agreements will be used for reduction of debt under the Company’s current facility with K2 HealthVentures.

 

About VBI Vaccines Inc.

 

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

 

Website Home: http://www.vbivaccines.com/

News and Resources: http://www.vbivaccines.com/news-and-resources/

Investors: http://www.vbivaccines.com/investors/

 

 
 

 

Cautionary Statement on Forward-looking Information

 

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such forward-looking statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the Company’s ability to satisfy all of the conditions to the consummation of the transactions with Brii described above, the Company’s ability to comply with its obligations under its loan agreement with K2 HealthVentures, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the COVID-19 pandemic and the continuing effects of the COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to successfully manufacture and commercialize PreHevbrio/PreHevbri; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of pipeline candidates and the commercialization of PreHevbrio/PreHevbri; the ability to obtain appropriate or necessary regulatory approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 13, 2023, and filed with the Canadian security authorities at sedar.com on March 13, 2023, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

 

VBI Contact

 

Nicole Anderson

Director, Corporate Communications & IR

Phone: (617) 830-3031 x124

Email: IR@vbivaccines.com

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 vbiv-20240214.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 vbiv-20240214_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 vbiv-20240214_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2024
Entity File Number 001-37769
Entity Registrant Name VBI Vaccines Inc/BC
Entity Central Index Key 0000764195
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One 160 Second Street
Entity Address, Address Line Two Floor 3
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 830-3031
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol VBIV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vbivaccines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm vbiv-20240214.xsd vbiv-20240214_lab.xml vbiv-20240214_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "VBIV", "nsuri": "http://vbivaccines.com/20240214", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "vbiv-20240214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "vbiv-20240214_lab.xml" ] }, "presentationLink": { "local": [ "vbiv-20240214_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://vbivaccines.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-006338-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-006338-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000764195 2024-02-14 2024-02-14 iso4217:USD shares iso4217:USD shares false VBI Vaccines Inc/BC 0000764195 8-K 2024-02-14 A1 001-37769 160 Second Street Floor 3 Cambridge MA 02142 (617) 830-3031 false false false false Common Shares, no par value per share VBIV NASDAQ false